Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some core pharmacology and the grapefruit juice interaction are supported by the provided label excerpts, but most supplement-interaction claims (St. John’s wort, red yeast rice, garlic, CoQ10, omega-3/fish oil, green tea extract, probiotics) are not supported by the supplied prescribing information. The cardiovascular prevention phrasing is only partially supported by the provided indication text.
Category Scores
Accurate Statements
Lipitor works by inhibiting the production of cholesterol in the liver, reducing blood low-density lipoprotein (LDL) cholesterol.
Label section 12.1 describes LIPITOR as a selective/competitive inhibitor of HMG-CoA reductase (cholesterol synthesis in the liver) and indicates it reduces LDL-C.
Grapefruit and grapefruit juice can increase the levels of Lipitor in the blood.
Label section 7.2 states grapefruit juice contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive consumption.
Unsupported Statements
St. John's Wort can interact with Lipitor, reducing its effectiveness.
No support in the provided label excerpts for St. John's wort interaction with atorvastatin.
St. John's Wort interacting with Lipitor can increase the risk of side effects.
No support in the provided label excerpts for any St. John's wort/atorvastatin safety consequence.
Red yeast rice can interact with Lipitor.
No support in the provided label excerpts for red yeast rice interaction with atorvastatin.
Red yeast rice interaction with Lipitor can increase the risk of muscle damage and other side effects.
No support in the provided label excerpts linking red yeast rice to muscle damage/side effects with atorvastatin.
Garlic supplements can interact with Lipitor.
No support in the provided label excerpts for garlic supplement interaction with atorvastatin.
Garlic supplements interacting with Lipitor can increase the risk of bleeding and other side effects.
No support in the provided label excerpts for garlic/atorvastatin and bleeding risk.
Coenzyme Q10 (CoQ10) can interact with Lipitor.
No support in the provided label excerpts for CoQ10 interaction with atorvastatin.
CoQ10 interacting with Lipitor can reduce its effectiveness.
No support in the provided label excerpts for CoQ10 affecting atorvastatin effectiveness.
CoQ10 interacting with Lipitor can increase the risk of side effects.
No support in the provided label excerpts for CoQ10/atorvastatin safety consequence.
Omega-3 fatty acids (fish oil supplements) can interact with Lipitor.
No support in the provided label excerpts for omega-3/fish oil interaction with atorvastatin.
Omega-3 fatty acids interacting with Lipitor can increase the risk of bleeding and other side effects.
No support in the provided label excerpts for omega-3/fish oil affecting bleeding risk with atorvastatin.
Green tea extract can interact with Lipitor.
No support in the provided label excerpts for green tea extract interaction with atorvastatin.
Green tea extract interacting with Lipitor can increase the risk of side effects.
No support in the provided label excerpts for green tea extract/atorvastatin safety consequence.
Probiotics can interact with Lipitor.
No support in the provided label excerpts for probiotic interaction with atorvastatin.
Probiotics interacting with Lipitor can reduce its effectiveness.
No support in the provided label excerpts for probiotics affecting atorvastatin effectiveness.
Probiotics interacting with Lipitor can increase the risk of side effects.
No support in the provided label excerpts for probiotics/atorvastatin safety consequence.
Contradictions
Important Omissions
Cardiovascular disease prevention wording is only partially supported by the provided indication excerpt; the label excerpt supplied does not explicitly state “prevent cardiovascular disease.”
Importance:
Moderate
For the grapefruit-to-skeletal muscle/side-effect risk linkage, the provided label excerpts show increased atorvastatin exposure and discuss myopathy/rhabdomyolysis risk generally, but do not explicitly state that grapefruit specifically can cause muscle damage/side effects.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about many supplement interactions (including bleeding and effectiveness reduction) could mislead patients/clinicians. The grapefruit interaction is supported, but its specific linkage to muscle damage/side effects is not explicitly supported in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Many supplement-interaction claims are not supported by the provided label excerpts.
Suggested Improvement
Limit interaction statements to those explicitly supported in the supplied label sections (e.g., grapefruit juice via CYP3A4 inhibition, and the listed drug classes/agents associated with increased myopathy risk). Rephrase grapefruit-related safety consequences to avoid explicit linkage not stated in the provided grapefruit section.